Medicines360 Appoints Lisa David as Chair of the Board of Directors, Strengthening its Commitment to Women’s Health

David brings over 30 years of experience in the public health and healthcare sectors to Medicines360

SAN FRANCISCO — Medicines360, a global nonprofit pharmaceutical organization specializing in women’s health, announced the appointment of Lisa David as Chair of the Board of Directors, effective January 1, 2024. With decades of experience in the reproductive health community, Ms. David will bring invaluable insights and leadership to Medicines360.

“I am honored to contribute to Medicines360 in this new role — I know trailblazing work lies ahead,” said Ms. David. “Women consistently face inequitable, daunting barriers to accessing the essential medicines and health innovations they need. Together, we will break down those barriers and democratize health care, making a meaningful impact in the health of women.”

Ms. David currently serves as President and CEO of Public Health Solutions (PHS), an organization working to improve health outcomes in New York City’s most vulnerable communities. Under her leadership, PHS provides underserved communities with essential services, including maternal and child health support and sexual and reproductive health services, among many others.

“Ms. David has been a crucial leader and a tireless advocate for women across the country throughout her renowned career,” said Medicines360 CEO and Director Andrea Olariu. “Ms. David’s extensive experience in the women’s health space, along with her deep commitment to building a society where all people have a right to health, will be essential to advancing Medicines360’s mission as we work to swiftly expand equitable access to care. We are proud that she will be assuming the role of Chair of the Board of Directors.”

Ms. David previously served as the Executive Vice President and Chief Operating Officer of the Planned Parenthood Federation of America (PPFA), where she led strategic support for Planned Parenthood’s affiliate health care operations both across the United States, as well as in Africa and South America. In her time at PPFA, Ms. David led initiatives to improve patient service and engagement and to expand clinical research and clinical quality programs, among many other accomplishments. Before joining PPFA, Ms. David served as Vice Chair for Administration of the Department of Obstetrics and Gynecology at the Columbia School of Physicians and Surgeons, where her leadership helped to build the quality and scope of subspecialty clinical programs.

Ms. David is nationally recognized for her ability to drive toward health equity; in addition to her leadership at Medicines360 and PHS, she serves on the board of National Network of Public Health Institutes, and the board of The Human Services Council. Ms. David also previously served on the board of trustees of the Women’s Health Activist Movement Global.

Press contact:
Anna Britt
Waxman Strategies

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.